Jasper Therapeutics, a biotechnology company, went public via a SPAC merger with Amplitude Healthcare Acquisition, a special purposes acquisition company, in a $490m deal. Investors in the PIPE include Federated Hermes Kaufmann Funds, Avego, Velan Capital, Metalmark, Amgen, Apeiron Investment, Kingdon Capital Management, Woodline Partners, Abingworth, Qiming Venture Partners, Surveyor Capital, Roche Venture Fund and Alexandria Venture Investments. “We would like to thank our financial partners at Amplitude and our prestigious group of investors. This transaction provides significant capital to accelerate the development of our two innovative programs, Jasper’s first-in-class clinical stage anti-CD117 antibody transplant conditioning agent and in parallel our groundbreaking research stage Engineered Hematopoietic Stem Cell platform, both of which have the potential to transform the field and expand hematopoietic stem cell therapy cures to a far greater number of patients than is possible today," Bill Lis, Jasper Therapeutics Chairman and CEO.